Brands
SHISEIDO announces Tamannaah Bhatia as the first brand ambassador in India
Mumbai: In a groundbreaking move that showcases the ever-expanding global reach of Japanese beauty and cosmetics giant SHISEIDO, the company in collaboration with its India distributor, Baccarose Perfumes & Beauty Products Pvt. Ltd. has appointed Tamannaah Bhatia as its first-ever brand ambassador in India for brand SHISEIDO Skincare range.
Bhatia, the versatile and beloved Bollywood star, has achieved a momentous milestone in her illustrious career by becoming the very first Indian brand ambassador for SHISEIDO.
Bhatia, known for her mesmerizing on-screen presence and her dedication to her craft, represents the perfect embodiment of SHISEIDO’s values of elegance, innovation, and individuality. Her natural beauty, combined with her ability to effortlessly adapt to various roles and styles, makes her an ideal choice as SHISEIDO’s brand ambassador for India.
“I am absolutely thrilled to be associated with SHISEIDO, a brand that has consistently set the standard for excellence in beauty for over a century. SHISEIDO’s commitment to innovation, quality, and celebrating individuality resonates with me on a personal level. I believe that beauty is not just about external appearance, but also about feeling confident and empowered in your own skin,” commented Bhatia.
SHISEIDO Asia Pacific VP fragrance and cosmetics division Nicolas Baudonnet, shared his thoughts on this momentous announcement saying, “We are delighted to welcome Tamannaah Bhatia into the SHISEIDO family. Her charisma, talent, and timeless beauty resonates with our brand’s core values, making her the perfect choice to represent SHISEIDO in India. We look forward to working closely with Tamannaah and believe that her association with our brand will help us connect with our consumers on a deeper level.
We are committed to bringing the best of SHISEIDO to the Indian beauty market. With the appointment of Tamannaah and expanding our presence in the market with the opening of our first brand SHISEIDO store in Mumbai, we are looking forward to bringing Indian beauty enthusiasts on an exciting journey ahead with the brand.”
The partnership between Tamannaah Bhatia and SHISEIDO represents a significant moment in the world of beauty and entertainment. It marks SHISEIDO’s unwavering commitment to connecting with the diverse and dynamic Indian market while recognizing Tamannaah’s exceptional talent, timeless beauty, and influence on fans across the nation.
Baccarose Perfumes & Beauty Products Pvt. Ltd. Kadambari Lakhani said, “This exciting collaboration not only marks a significant milestone for us and for SHISEIDO but also symbolizes the harmonious fusion of Japanese precision and Indian vibrancy. Tamannaah Bhatia embodies the essence of timeless beauty and has captivated audiences with her talent and charisma. This partnership promises to bring together the rich traditions of Japanese skincare innovation with the dazzling allure of Bollywood glamour, setting the stage for an enchanting journey into the world of beauty that transcends cultural boundaries.”
Baccarose Perfumes & Beauty Products Pvt. Ltd. senior VP & group marketing Villoo Daji said, “SHISEIDO’s choice of Tamannaah Bhatia as their first brand ambassador in India reflects the brand’s dedication to enhancing the beauty experiences of Indian consumers.
SHISEIDO’s Skincare range is an induction into the skincare regimen which is simple and has a proven efficacy after detailed testing on Asian skin. This partnership is set to inspire beauty enthusiasts and consumers across the country to explore the world of SHISEIDO’s skincare and makeup products, renowned for their outstanding quality and effectiveness.
The collaboration between Bhatia and SHISEIDO promises exciting new ventures, innovative campaigns, and an enhanced brand experience for beauty enthusiasts across India.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
